Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.

Psychedelic-assisted psychotherapy (PAP) may be beneficial for treating conditions such as substance use disorders and PTSD.

• Emerging evidence suggests that compounds like MDMA, psilocybin, and LSD could improve outcomes in various psychiatric conditions when used alongside therapy.
• Previous research has highlighted ethnoracial differences in the metabolism and efficacy of psychotropic drugs, but no studies have examined these differences in the context of psychedelics.
• Most psychedelic research has focused on White populations, neglecting the experiences of Black, Indigenous, and People of Color (BIPOC).
• Ignoring ethnoracial diversity in research may limit the generalizability of findings related to PAP.
• The article discusses the need to consider cultural, clinical, and public health factors to better address the needs of diverse clients in therapeutic settings.

AI simplified